Celldex Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CLDX Nasdaq 2830 www.celldex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celldex Therapeutics, Inc.

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year? - Jul 24th, 2026 7:40 am
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss - Jul 22nd, 2026 4:02 am
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study - Jul 22nd, 2026 3:33 am
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff? - Jul 21st, 2026 4:52 pm
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis - Jul 21st, 2026 2:01 pm
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? - Jul 20th, 2026 5:26 am
Celldex Announces Planned Transition of Chief Financial Officer - Jul 15th, 2026 2:01 pm
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? - Jun 30th, 2026 7:21 am
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight - Jun 24th, 2026 8:31 am
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now - Jun 19th, 2026 6:24 am
Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum - Jun 14th, 2026 6:16 pm
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting - Jun 14th, 2026 8:21 am
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting - Jun 14th, 2026 3:15 am
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress - Jun 10th, 2026 2:01 pm
[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - May 18th, 2026 10:30 pm
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals - May 12th, 2026 4:17 pm
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 3:55 pm
Celldex Reports First Quarter Financial Results and Provides Corporate Update - May 7th, 2026 2:01 pm
Innoviva (INVA) Tops Q1 Earnings Estimates - May 6th, 2026 7:45 pm
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - May 4th, 2026 7:55 am